The main focus of the research in our lab is on the cellular and molecular mechanisms that lead to the onset and progression of amyotrophic lateral sclerosis (ALS). We combine biochemistry, molecular biology and use both cellular and in vivo models to investigate the molecular mechanisms involved in ALS pathogenesis. Our long term aim is to identify new candidate agents that will be able to slow or stop the progression of the disease. These agents will be tested in pre-clinical studies and will be the basis to develop new drugs for the treatment of ALS and other neurodegenerative disorders.
| Ben-Gurion University of the Negev | |
|---|---|
| Foundation year | 2013 |
| Director | Dr. Adrian Israelson |
| Principal investigator | Dr. Adrian Israelson |
| Contact information | |
|---|---|
| Address | Ben Gurion st. |
| Contact | Dr. A. Israelson |
| Phone | 00972 8 6477343 |
| adriani@bgu.ac.il | |
| Website | Visit the website |
Publications
- Shani T, Levy M, and Israelson A. Assay to measure nucleocytoplasmic transport in real time using motor neuron-like NSC-34 cells. J. Vis. Exp. (in press).
- Leyton-Jaimes M*, Benaim C*, Abu-Hamad S*, Guetta A, Kahn J, Bucala R, and Israelson A. Endogenous Macrophage Migration Inhibitory Factor Reduces the Accumulation and Toxicity of Misfolded SOD1 in a Mouse Model of ALS. Proc. Natl. Acad. Sci. USA 113, 10198-10203 (2016).
- Banerjee V*, Shani T, Katzman B, Vyazmensky M, Papo N, Israelson A and Engel S. SOD1–derived peptide inhibits amyloid-like aggregation of misfolded SOD1. ACS Chem. Neurosci. (2016).
- Abu-Hamad S and Israelson A. Macrophage Migration Inhibitory Factor as a Component of Selective Vulnerability of Motor Neurons in ALS. Rare Diseases 3:1, e1061164 (2015).
- Israelson A, Ditsworth D, Sun S, Song SW, Liang J, Hruska-Plochan M, McAlonis-Downes M, Abu-Hamad S, Zoltsman G, Shani T, Maldonado M, Bui A, Navarro M, Zhou H, Marsala M, Kaspar BK, Da Cruz S and Cleveland DW#. Macrophage Migration Inhibitory Factor as a Chaperone Inhibiting Accumulation of Misfolded SOD1. Neuron 86, 218-232 (2015) – Comments on this article: i. Highlighted in Neuron with a preview article ii. Recommended by “Faculty of 1000”
Restricted information
| Serving population | |
|---|---|
| Serving population | Unknown |
| Patient resources | |
|---|---|
| Population based register | No |
| Clinic based register | No |
| Geographically matched controls | No |
Banks
There are no banks for this centre
| Research activities | |
|---|---|
| Clinical management research | No |
| Neuro epidemiology | No |
| Neuro physiology | No |
| Neuro imaging | No |
| Neuro psychology | No |
| Neuro pathology | No |
| Genomics | No |
| Transcriptomics | No |
| Metabolomics | No |
Clinical Trials - Industry sponsored
There are no clinical trials for this centre
Clinical Trials - Investigator initiated
There are no clinical trials for this centre